Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117031) titled 'A single-arm, Phase II clinical study of adebelumab in combination with targeted therapy and chemotherapy for the conversion therapy of patients with unresectable colorectal cancer liver metastases' on Jan. 19.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shanxi Hospital of Cancer Hospital, Chinese Academy of Medical Sciences
Condition:
Colorectal cancer
Intervention:
Single-arm:Adelbelimab: Intravenous infusion, 1200 mg dose, D1, Q2W
Cetuximab: Intravenous infusion, 500 mg/m^2 dose, D1, Q2W (RAS/BRAF wild-type with primary lesion in left-sided colon)
Bevacizumab: IV infusion, ...